PARP inhibitor resistance: the underlying mechanisms and clinical implications
Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
S Li, L Wang, Y Wang, C Zhang, Z Hong… - Journal of Hematology & …, 2022 - Springer
Continuous cell division is a hallmark of cancer, and the underlying mechanism is tumor
genomics instability. Cell cycle checkpoints are critical for enabling an orderly cell cycle and …
genomics instability. Cell cycle checkpoints are critical for enabling an orderly cell cycle and …
Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP
Y Chen, Q Hao, S Wang, M Cao… - Proceedings of the …, 2021 - National Acad Sciences
p53 inactivation is highly associated with tumorigenesis and drug resistance. Here, we
identify a long noncoding RNA, the RNA component of mitochondrial RNA-processing …
identify a long noncoding RNA, the RNA component of mitochondrial RNA-processing …
Pan-cancer analysis reveals molecular patterns associated with age
Older age is a strong risk factor for several diseases, including cancer. The etiology and
biology of age-associated differences among cancers are poorly understood. To address …
biology of age-associated differences among cancers are poorly understood. To address …
[HTML][HTML] Mechanism of PARP inhibitor resistance and potential overcoming strategies
PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose)
polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by …
polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by …
The role of poly (ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review
M Patel, S Nowsheen, S Maraboyina, F Xia - Cell & Bioscience, 2020 - Springer
Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors represent one of the successful
novel approaches to targeted cancer treatment. Indeed, the US Food and Drug …
novel approaches to targeted cancer treatment. Indeed, the US Food and Drug …
The PARP enzyme family and the hallmarks of cancer part 1. cell intrinsic hallmarks
MA Demény, L Virág - Cancers, 2021 - mdpi.com
Simple Summary Poly (ADP-ribose) polymerase (PARP) proteins regulate DNA damage
correction, replication, and gene transcription. By controlling pivotal aspects of these …
correction, replication, and gene transcription. By controlling pivotal aspects of these …
PARP inhibitors in combination with radiotherapy: to do or not to do?
A Barcellini, P Loap, K Murata, R Villa, Y Kirova… - Cancers, 2021 - mdpi.com
Simple Summary Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-
I), the feasibility and safety of their combination with radiotherapy (RT) are unclear. The …
I), the feasibility and safety of their combination with radiotherapy (RT) are unclear. The …
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside
I Meattini, L Livi, N Lorito, C Becherini, M Bacci… - Cancer treatment …, 2022 - Elsevier
Major advances have been made in precision medicine of breast cancer patients with a
series of molecular targeted therapies now in clinical use or in late clinical development …
series of molecular targeted therapies now in clinical use or in late clinical development …
PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities
WH Li, F Wang, GY Song, QH Yu, RP Du… - Frontiers in …, 2023 - frontiersin.org
Background: Since its discovery, poly (ADP-ribose) polymerase 1 (PARP-1) has been
extensively studied due to its regulatory role in numerous biologically crucial pathways …
extensively studied due to its regulatory role in numerous biologically crucial pathways …